OTHER GROUP COMPANIES
- Login to Trade
- Login to DP
- Karvy Customer
-
OTHER GROUP COMPANIES
-
- Home
Strides Pharma Science gained 1.1% to Rs 449.90 after the drug company on Monday announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. received approval for oseltamivir phosphate for oral suspension from the USFDA.
The product is bioequivalent and therapeutically equivalent to the reference listed drug, Tamiflu of Hoffmann-La Roche, Inc. According to IQVIA MAT November 2020 data, the US market for Oseltamivir Phosphate for oral suspension was approximately $ 132 million.
The product will be manufactured at the companys facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval.
Strides Pharma Science is a global pharmaceutical company. The company mainly operates in the regulated markets and has an in Africa for Africa strategy along with an institutional business to service donor‐funded markets. The company focuses on ?difficult to manufacture? products that are sold in over 100 countries.
The company reported a consolidated net loss of Rs 162.55 crore in Q2 FY22 as against a net profit of Rs 80.94 crore in Q2 FY21. Revenue from operations during the quarter fell by 9.08% YoY to Rs 721.47 crore.
Powered by Capital Market - Live News
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
May 16, 2022
The laws of the financial world are different from the physical world. You can have prolonged periods of time, when sanity takes a back seat and excesses happen.
R. Venkataraman Aug 20, 2021
Retail trading or day trading has exploded because of falling brokerage rates, democratization of information, higher transparency and mobile platforms.
R. Venkataraman Jun 15, 2021
My simple message for dear readers is, if you don’t have any desperate need for funds, then don’t do anything.
R. Venkataraman May 12, 2021
The blow up of a US hedge fund has resulted in WhatsApp university offering many courses on what went wrong with Bill Hwang and Archegos.
R. Venkataraman Apr 09, 2021
The expensive valuations have been sustained by strong rebound in corporate earnings which led to ~8% upgrade in FY22 Nifty EPS since October 2020.
R. Venkataraman Mar 26, 2021
We believe the interest rates are likely to have bottomed due to inflationary pressure, large government borrowings and normalizing credit growth. Hence rate sensitive sectors should be avoided in our view.
R. Venkataraman Feb 17, 2021
As markets make new highs, one gets more emails and messages, which highlight the accomplishments of traders who have found a formula for making money.
R. Venkataraman Jan 27, 2021
Data does not seem to convincingly prove that short periods of high returns are always followed by meagre returns. Only in 4 instances, we had negative returns in the subsequent year.
R. Venkataraman Jan 01, 2021
Since September end, Bankex is up 16% with large banks like ICICI Bank, Bandhan up 20-27%, Housing Finance Companies like Repco, LICHF, PNB Housing are up 50%-100% from their six-month lows.
R. Venkataraman Oct 13, 2020
Morgan Housel’s 'The Psychology of Money' explains in detail the role of human biases in investment decisions.
R. Venkataraman Sep 26, 2020
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
